Research discovers potential new Rx target for colon cancer

September 12, 2017
Credit: Louisiana State University

Genetic research conducted at LSU Health New Orleans School of Medicine and Stanley S. Scott Cancer Center demonstrated for the first time that a novel protein can cause normal cells in the lining of the colon to become malignant, grow and spread, as well as take on the characteristics of stem cells. The work, which details the process, is published online in Nature Research's Scientific Reports.

SATB2 is a novel "transcription factor" - a protein "switch" that controls which genes are turned on or off inside a cell. Drs. Rakesh Srivastava and Sharmila Shankar identified it in the so-called "cancer stem cells" - cancer cells that behave like stem cells. Cancer stem cells are a small subset of in tumors that are not only capable of renewing themselves, but also giving rise to other cells needed by the tumors to survive and grow. These cells are more resistant than typical cancer cells to standard chemotherapeutic agents and can persist in the body even after treatment. The cancer stem cells are thought to be a major cause of treatment failure, disease relapse and metastasis. Certain signals can turn a regular cancer cell into a , making it resistant to treatment. SATB2 appears to be a master regulator of that process, controlling several of the mechanisms involved.

When Drs. Srivastava and Shankar compared normal human colorectal and tissue with human colorectal cancer cell lines and primary colorectal tissues, they found that while SATB2 is not active in normal colorectal tissue, it is highly active in colorectal cancer cells.

To study SATB2's role in colorectal cancer, the researchers forced the SATB2 gene to make extra copies of the SATB2 protein in . The cells changed, displaying enhanced cell growth, motility, migration and invasion. Further analysis revealed markers and a master cell ability - the cells could produce any kind of cell needed just like other stem cells. They became cancer stem cells. The researchers also found these cells had a much greater ability to survive and proliferate.

Silencing SATB2 in the colorectal cancer cells not only suppressed cell growth, motility and colony formation, but the characteristics of cancer stem were absent. This means that if agents are identified that can block SATB2, they may be used, along with standard of care, to prevent cancer relapses and metastasis.

"Since the SATB2 protein is highly expressed in the colorectal cell lines and tissues, it can be an attractive target for therapy, diagnosis and prognosis," notes Dr. Rakesh Srivastava, Professor of Genetics at LSU Health New Orleans School of Medicine and Stanley S. Scott Cancer Center.

"Importantly, SATB2 is present not only in colon cancer, but in other cancers as well," adds Dr. Sharmila Shankar, PhD, Associate Professor of Genetics at LSU Health New Orleans School of Medicine and Stanley S. Scott Cancer Center.

Explore further: ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression

More information: Wei Yu et al, SATB2/β-catenin/TCF-LEF pathway induces cellular transformation by generating cancer stem cells in colorectal cancer, Scientific Reports (2017). DOI: 10.1038/s41598-017-05458-y

Related Stories

ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression

August 2, 2017
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from Oncoceutics, Inc., USA and ...

Researchers publish new findings on influence of high-fat diet on colorectal cancer

July 6, 2017
Poor diet is associated with 80% of colorectal cancer cases, but the exact pathways by which diet leads to cancer are not known.

Potential new colorectal cancer treatment target identified

October 7, 2012
(HealthDay)—The cell surface marker carcinoembryonic antigen-related cell adhesion molecule 6 (CD66c) is a novel marker for colorectal cancer stem cell isolation, which halts tumor growth when silenced, according to research ...

Researchers identify new stem cell population important in the growth of colon cancer

June 16, 2015
Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly ...

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified

December 1, 2016
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring ...

Oral milk thistle extract stops colorectal cancer stem cells from growing tumors

April 20, 2015
In results presented at the American Association for Cancer Research (AACR) Annual Meeting 2015, a University of Colorado Cancer Center study shows that orally administering the chemical silibinin, purified from milk thistle, ...

Recommended for you

Team identifies a switch that may help target dormant cancer cells

September 26, 2017
A study by scientists at the University of Arizona and the University of Pittsburgh may hold the key to targeting dormant—or inactive —cancer cells, which are resistant to chemotherapy and other treatments. The results ...

Researchers discover how enzyme 'shape-shifts' in drug-resistant leukemia

September 26, 2017
St. Jude Children's Research Hospital structural biologists have deciphered how the structure of the enzyme called Abl regulates its activity, enabling the enzyme to switch itself on and off. Understanding Abl's regulation ...

Powerful drug combo gangs up to tackle triple-negative breast cancer

September 26, 2017
In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death.

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.